
IRadimed Corp IRMD.OQ IRMD.O is expected to show a rise in quarterly revenue when it reports results on February 13 for the period ending December 31 2024
The Winter Springs Florida-based company is expected to report a 9.7% increase in revenue to $19.145 million from $17.45 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on January 10 2025, for the period ended December 31, was for revenue between $19.20 million and $19.40 million.
LSEG's mean analyst estimate for IRadimed Corp is for earnings of 44 cents per share. The company's EPS guidance on October 31 2024, for the period ended December 31, was between $0.42 and $0.45
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for IRadimed Corp is $65.00, above its last closing price of $60.35.
This summary was machine generated February 11 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)